Clinical Trial Update: PRC-063 in an ADULT Workplace Environment [Phase 3]

View source ↗

Summary

Phase 3 trial of PRC-063 for attention-deficit/hyperactivity disorder in adults completed, sponsored by Rhodes Pharmaceuticals, L.P., evaluating an adult workpl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• PRC-063 (PRC-063)

Snippet

Sponsor: Rhodes Pharmaceuticals, L.P. | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: COMPLETED